Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 158)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
Dazolam
DB00683
Dea no. 2884
Dea No. 2884
DEA No. 2884
Dormicum
Dormicum (TN)
EINECS 261-774-5
Hydrochloride, midazolam
|
LS-77780
Maleate, midazolam
Mezolam
Midanium
midazolam
Midazolam
Midazolam (JAN/INN)
Midazolam [INN:BAN:JAN]
Midazolam base
Midazolam Base
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
nchembio747-comp32
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
|
|
2 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
3 |
|
Metformin |
Approved |
Phase 4 |
|
657-24-9 |
14219 4091 |
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
4 |
|
Insulin aspart |
Approved |
Phase 4 |
|
116094-23-6 |
16132418 |
Synonyms:
(AspB28)-human insulin
1024611-56-0
116094-23-6
139532-40-4
28(sup B)-L-Aspartic acid-insulin (human)
877034-90-7
Aspart
Aspart insulin
Aspart Insulin
AspB28-insulin (human)
B28-Aspart-Insulin
B28-Asp-insulin
INA-X 14
Insulin aspart
Insulin aspart [USAN]
|
Insulin aspart protamine
Insulin aspart protamine recombinant
Insulin aspart recombinant
Insulin X14
Insulin, aspart protamine, human
Insulin, aspart, human
Insulin,aspart protamine
Insulina asparta
LS-185932
NovoLog
Novolog mix 70/30
NovoMix 30
NovoRapid
NovoRapid 30 Mix
UNII-D933668QVX
|
|
5 |
|
Histamine |
Approved, Investigational |
Phase 4 |
|
51-45-6, 75614-87-8 |
774 |
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
|
Histamine
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
β-Imidazolyl-4-ethylamine
|
|
6 |
|
Diphenhydramine |
Approved, Investigational |
Phase 4 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
147-24-0
147-24-0 (HYDROCHLORIDE)
2-(benzhydryloxy)-N,N-dimethylethylamine
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride
2-(diphenylmethoxy)-N,N-dimethylethanamine
2-(Diphenylmethoxy)-N,N-dimethylethylamine
2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine
2-benzhydryloxyethyl-N,N-dimethylammonium
2-benzhydryloxy-N,N-dimethylethanamine
2-diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
2PM
58-73-1
88637-37-0 (citrate (1:1))
a-(2-Dimethylaminoethoxy)diphenylmethane
AB00053460
AC-13704
AC1L1F65
AKOS003658554
Aleryl
Alledryl
Allerdryl
Allergan
Allergan B
Allergeval
Allergical
Allergina
Allergival
Allermax Caplets
Aller-Med
alpha-(2-Dimethylaminoethoxy)diphenylmethane
Amidryl
Antistominum
Antitussive
Antomin
Automin
Bagodryl
Banophen
Banophen Caplets
Baramine
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
Beldin
Belix
Bena
Benachlor
Benadrin
Benadryl
Benadryl (hydrochloride)
Benadryl Allergy
BENADRYL HCl
Ben-allergin
Benapon
Bendylate
Benhydramin
Benodin
Benodine
Benylan
Benylin
Benzantin
Benzantine
Benzhydramine
Benzhydraminum
Benzhydril
Benzhydroamina
Benzhydryl
beta-Dimethylamino-aethyl-benzhydryl-aether
beta-Dimethylamino-aethyl-benzhydryl-aether [German]
beta-Dimethylaminoethanol diphenylmethyl ether
beta-dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethylbenzhydrylether
Betramin
BIDD:GT0152
BPBio1_000275
BRD-K47278471-003-05-7
BRN 1914136
BSPBio_000249
BSPBio_002219
CAS-147-24-0
CCRIS 1959
CHEBI:127629
CHEBI:4636
CHEMBL657
CID3100
Citrate, diphenhydramine
Compoz
CPD-10890
D00300
Dabylen
DB01075
DB06975
Debendrin
Dermistina
Dermodrin
Desentol
Diabenyl
Diabylen
Dibendrin
Dibenil
Dibondrin
Difedryl
Difenhidramina
Difenhidramina [INN-Spanish]
Difenhydramin
Difenhydramine
Difenidramina
Difenidramina [Italian]
Dihidral
Dimedrol
Dimedrol base
Dimedrolum
Dimedryl
Dimehydrinate
Dimethylamine benzhydryl ester
|
Diphamine
Diphantine
Diphen
Diphen Cough
Diphenhist
Diphenhist Captabs
diphenhydramine
Diphenhydramine
Diphenhydramine (JP15/INN)
Diphenhydramine [INN:BAN:JAN]
Diphenhydramine Base
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
Diphenhydramine HCl
Diphenhydramine hydrochloride
DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE
Diphenhydraminum
Diphenhydraminum [INN-Latin]
Diphenylhydramin
Diphenylhydramine
DivK1c_000368
Dobacen
Dormarex 2
Dormin
Dryistan
Drylistan
Dylamon
EINECS 200-396-7
Etanautine
FAR 90X2
Genahist
Histaxin
HMS2089E06
HSDB 3066
Hyadrine
Hydramine
Hydrochloride, diphenhydramine
Hyrexin
I14-6749
Ibiodral
IDI1_000368
KBio1_000368
KBio2_001460
KBio2_004028
KBio2_006596
KBio3_001439
KBioGR_001099
KBioSS_001460
L000227
Lopac0_000377
Lopac-D-3630
LS-68208
Medidryl
Mephadryl
MLS002222276
MolPort-001-783-508
N-(2-(diphenylmethoxy)ethyl)-N,N-dimethylamine
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
N-(Benzhydryloksy-etylo)dwumetyloamina
N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]
N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride
N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE
Nausen
NCGC00015335-01
NCGC00015335-02
NCGC00015335-03
NCGC00015335-10
NCGC00024414-03
NCGC00024414-04
nchembio747-comp18
NCI60_002916
NCI60_022782
Nervine Nighttime Sleep-Aid
NINDS_000368
Novamina
NSC665800
Nytol Quickcaps
Nytol Quickgels
O-benzhydryldimethylaminoethanol
O-Benzhydryldimethylaminoethanol
Oprea1_254625
PM 255
Prestwick0_000065
Prestwick1_000065
Prestwick2_000065
Prestwick3_000065
Probedryl
Restamin
Restamin (TN)
Rigidil
S51
Siladryl
Silphen
Sleep-Eze D
Sleep-Eze D Extra Strength
SMR001307259
SPBio_000961
SPBio_002170
Spectrum_000980
Spectrum2_000961
Spectrum3_000400
Spectrum4_000520
Spectrum5_000915
STK103720
STOCK2S-94461
Syntedril
Syntodril
TL8003758
Twilite Caplets
UNII-8GTS82S83M
Unisom Sleepgels Maximum Strength
α-(2-dimethylaminoethoxy)diphenylmethane
Α-(2-dimethylaminoethoxy)diphenylmethane
β-dimethylaminoethanol diphenylmethyl ether
Î’-dimethylaminoethanol diphenylmethyl ether
β-dimethylaminoethyl benzhydryl ether
Î’-dimethylaminoethyl benzhydryl ether
|
|
7 |
|
Buprenorphine |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
52485-79-7 |
40400 644073 |
Synonyms:
(-)-buprenorphine
(−)-buprenorphine
(-)-Buprenorphine
(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol
(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol
[5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol
17-Cyclopropylmethyl-4,5a-epoxy-7a-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
2-(N-Cyclopropylmethyl-4,5a-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6a-yl)-3,3-dimethyl-2-butanol
2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol
2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol
2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
52485-79-7
53152-21-9 (hydrochloride)
6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,
6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI)
6029-M
AC1L23NL
AC1L9B1M
AC1LD8IH
Buprel
Buprenex
Buprenophine
Buprenorfina
Buprenorfina [INN-Spanish]
buprenorphine
Buprenorphine
Buprenorphine (JAN/INN)
Buprenorphine [INN:BAN]
Buprenorphine grünenthal brand
|
Buprenorphine Hcl
Buprenorphine hydrochloride
Buprenorphinum
Buprenorphinum [INN-Latin]
Buprex
C08007
C29H41NO4
CHEBI:3216
CHEMBL1201894
CHEMBL47085
CID40400
CID441363
CID5311033
CID6321408
CID644073
D07132
DB00921
DEA No. 9064
EINECS 257-950-6
Essex brand OF buprenorphine hydrochloride
Grünenthal brand OF buprenorphine
Grünenthal brand OF buprenorphine hydrochloride
Hydrochloride, buprenorphine
Key brand OF buprenorphine hydrochloride
LS-67682
MolPort-004-285-844
PDSP2_000111
Prefin
Probuphine
Reckitt and colman brand 1 OF buprenorphine hydrochloride
Reckitt and colman brand 2 OF buprenorphine hydrochloride
Reckitt benckiser brand OF buprenorphine hydrochloride
Reckitt brand OF buprenorphine hydrochloride
RX 6029 m
RX 6029M
RX-6029-m
RX-6029-M
Schering plough brand OF buprenorphine hydrochloride
Schering-plough brand OF buprenorphine hydrochloride
Subutex
Temgesic
Temgésic
Temgesic (TN)
UNII-40D3SCR4GZ
|
|
8 |
|
Promethazine |
Approved, Investigational |
Phase 4 |
|
60-87-7 |
4927 |
Synonyms:
(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
(Dimethylamino-2-propyl-10-phenothiazine hydrochloride
10-(2-(Dimethylamino)-2-methylethyl)phenothiazine
10-(2-(Dimethylamino)propyl)phenothiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(dimethylamino)propyl]phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl- (9CI)
10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-, radical ion(1+)
3277 RP
3389 R.p.
38878-40-9
4182 R.p.
4-27-00-01253 (Beilstein Handbook Reference)
60-87-7
73745-50-3
A-91033
AB00053535
AC-15939
AC1L1J92
Antiallersin
Aprobit
Atosil
Avomine
BPBio1_000744
BRN 0088554
BSPBio_000676
BSPBio_002777
C07404
Camergan
CCRIS 7056
CHEBI:8461
CHEMBL643
CID4927
D00494
DB01069
Dimapp
Dimethylamino-isopropyl-phenthiazin
Dimethylamino-isopropyl-phenthiazin [German]
Diphergan
Diprazin
Diprazine
Diprozin
DivK1c_000005
EINECS 200-489-2
Fargan
Fenazil
Fenetazina
Fenetazine
Genphen
Hiberna
Histargan
HMS2089E08
HSDB 3173
Hydrochloride, promethazine
IDI1_000005
Iergigan
InChI=1/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
Isophenergan
Isopromethazine
KBio1_000005
KBio2_001348
KBio2_003916
KBio2_006484
KBio3_001997
KBioGR_001697
KBioSS_001348
L000495
Lercigan
Lergigan
Lilly 01516
Lilly 1516
Lopac0_000899
LS-264
Metaryl
MolPort-001-783-684
N-(2'-dimethylamino-2'-methyl)ethylphenothiazine
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,α-trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine
|
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine hydrochloride
NCGC00015817-10
NCGC00089735-02
NCGC00089735-03
NCI60_001878
NCI-C60673
N-Dimethylamino-2-methylethyl thiodiphenylamine
NINDS_000005
NSC 30321
NSC30321
Oprea1_758749
Pelpica
Phargan
Phenargan
Phenergan
Phenerzine
Phenoject-50
Phensedyl
Pilothia
Pilpophen
Pipolfen
Pipolphen
Pipolphene
Prestwick0_000888
Prestwick1_000888
Prestwick2_000888
Prestwick3_000888
Pro-50
Proazaimine
Proazamine
Procit
Promacot
Promazinamide
Promergan
Promesan
Promet
Prometasin
Prometazin
Prometazina
Prometazina [INN-Spanish]
Prometazine
Prometh
Promethacon
Promethaine
Promethazin
promethazine
Promethazine
Promethazine (JAN/INN)
PROMETHAZINE (SEE ALSO PROMETHAZINE HYDROCHLORIDE 58-33-3)
Promethazine [INN:BAN]
Promethazine hydrochloride
PromethazineHcl
Promethazinum
Promethazinum [INN-Latin]
Promethegan
Promethiazine
Promezathine
Prorex
Protazine
Prothazin
Prothazine
Provigan
Pyrethia
Pyrethiazine
Remsed
Romergan
RP 3277
Rumergan
SKF 1498
SPBio_000799
SPBio_002895
Spectrum_000868
Spectrum2_000840
Spectrum3_001019
Spectrum4_001149
Spectrum5_000977
Tanidil
Thiergan
UNII-FF28EJQ494
Valergine
Vallergine
WLN: T C666 BN ISJ B1Y1&N1&1
WY 509
Zipan-25
|
|
9 |
|
Naloxone |
Approved, Vet_approved |
Phase 4 |
|
465-65-6 |
5284596 |
Synonyms:
(-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one
(−)-naloxone
(-)-Naloxone
(5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one
(5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one
12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone
12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one
17-Allyl-3,14-dihydroxy-4,5a-epoxymorphinan-6-one
17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one
1-N-Allyl-14-hydroxynordihydromorphinone
1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone
3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
357-08-4 (hydrochloride)
465-65-6
Abello brand OF naloxone hydrochloride
Abello, naloxone
BIDD:GT0110
Boots brand OF naloxone hydrochloride
BPBio1_000136
BRD-K67511046-003-03-7
Bristol myers squibb brand OF naloxone hydrochloride
Bristol-myers squibb brand OF naloxone hydrochloride
BRN 1089071
BSPBio_000122
C07252
CHEBI:7459
CHEMBL80
CID5284596
Curamed brand OF naloxone hydrochloride
Curamed, naloxon
D08249
DB01183
DBL Naloxone
DBL Naloxone (TN)
Dihydride, naloxone hydrochloride
EINECS 207-365-7
EN 1530 base
EN 1530 Base
endo Brand OF naloxone hydrochloride
HMS2090F20
HSDB 3279
Hydrobromide, naloxone
Hydrochloride dihydride, naloxone
Hydrochloride, naloxone
Lamepro brand OF naloxone hydrochloride
l-N-Allyl-14-hydroxynordihydromorphinone
l-N-Allyl-7,8-dihydro-14-hydroxynormorphinone
l-Naloxone
L-Naloxone
|
LS-187184
LS-92141
MolPort-002-536-640
Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy- (8CI)
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)- (9CI)
MRZ 2593 BR
MRZ 2593BR
MRZ 2593-BR
N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon
n-Allylnoroxymorphone
N-Allylnoroxymorphone
N-Allyl-noroxymorphone
Nalone
Nalossone
Nalossone [Dcit]
Nalossone [DCIT]
Naloxon curamed
Naloxon ratiopharm
Naloxona
Naloxona [INN-Spanish]
naloxone
Naloxone
Naloxone (INN)
Naloxone [INN:BAN]
Naloxone abello
Naloxone HCl
Naloxone hydrobromide
Naloxone hydrochloride
Naloxone hydrochloride dihydride
Naloxone hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxonratiopharm
Naloxon-ratiopharm
Naloxonum
Naloxonum [INN-Latin]
Narcan
Narcanti
Narcon
NCGC00024674-02
NSC 70413
NSC70413
PDSP2_001520
Prestwick0_000111
Prestwick1_000111
Prestwick2_000111
Prestwick3_000111
Ratiopharm brand OF naloxone hydrochloride
SERB brand OF naloxone hydrochloride
SMP1_000205
SPBio_002061
STOCK1N-69923
UNII-36B82AMQ7N
United drug brand OF naloxone hydrochloride
|
|
10 |
|
Carvedilol |
Approved, Investigational |
Phase 4 |
|
72956-09-3 |
2585 |
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
107741-96-8
14C-Labeled carvedilol
72956-09-3
AB1004830
AC-1641
AC1L1E0B
Artist
Artist (TN)
Atlana Pharma brand of carvedilol
Bio-0014
BM 14190
BM-14.190
BM-14190
BM-14-190
BRD-A10977446-001-04-8
BRD-A10977446-045-01-1
C043211
C06875
C2260
C24H26N2O4
carvedilol
Carvedilol
Carvédilol
Carvedilol (JAN/USAN/INN)
Carvedilol [USAN:INN:BAN:JAN]
Carvedilol hydrochloride
Carvedilol, (-)
Carvedilol, (-)-isomer
Carvedilol, (+)
carvedilol, (+-)-isomer
Carvedilol, (+)-isomer
Carvedilol, (+-)-isomer
carvedilol, (R)-isomer
Carvedilol, (R)-isomer
carvedilol, (S)-isomer
Carvedilol, (S)-isomer
Carvedilol, 14C labeled
carvedilol, 14C-labeled
Carvedilol, 14C-labeled
Carvedilolum
Carvedilolum [Latin]
CHEBI:3441
CHEMBL723
CID2585
Coreg
|
Coreg (TN)
Coreg CR
Coropres
Coropress
CPD000449280
D00255
DB01136
Dibloc
Dilatrend
DQ 2466
DQ-2466
EG-P042
Eucardic
GlaxoSmithKline brand of carvedilol
HMS2051N03
HMS2089B09
HMS2093E12
HSDB 7044
I06-0064
I06-1477
KBio2_002145
KBio2_004713
KBio2_007281
KBio3_002323
KBioGR_001252
KBioSS_002145
Kredex
L001243
Lakeside brand of carvedilol
LS-121875
MLS000758299
MLS000759508
MLS001424092
MolPort-003-666-814
NCGC00167832-01
NCGC00167832-02
NCGC00167832-03
Querto
Roche brand of carvedilol
SAM001246736
SAM001247021
SK&F-105517
SKF 105517
SMR000449280
SPBio_001885
Spectrum_001665
Spectrum2_001673
Spectrum3_001182
Spectrum4_000636
Spectrum5_001436
STK621453
TL8005080
UNII-0K47UL67F2
|
|
11 |
|
Propranolol |
Approved, Investigational |
Phase 4 |
|
525-66-6 |
4946 |
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
13013-17-7
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
AY 64043
AY-20694
Bedranol
Beprane
Berkolol
Beta Neg
Betachron
Betadren
Betalong
Beta-Neg
beta-Propranolol
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
BPBio1_001040
b-Propranolol
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
C07407
C16H21NO2
Cardinol
Caridolol
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
cMAP_000071
Corpendol
D,L-Propranolol
D08443
DB00571
Deralin
Dexpropranolol
DivK1c_000023
Dl-Propranolol Hydrochloride
DL-Propranolol hydrochloride
Dociton
Duranol
Efektolol
EINECS 208-378-0
EINECS 235-867-6
Elbrol
etalong
Etalong
Euprovasin
Frekven
Herzbase
HMS2090L21
Hydrochloride, propranolol
ICI 45520
IDI1_000023
Ikopal
Inderal
Inderal hydrochloride
Inderal La
Inderalici
Inderex
Inderide
INDERIDE-40/25
INDERIDE-80/25
|
Inderol
Indobloc
Innopran XL
InnoPranXL
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
Lopac0_000896
LS-122410
LS-184129
Migrastat
MolPort-001-794-623
Naprilin
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Pranolol
Prano-Puren
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
propranolol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol [INN:BAN]
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol hydrochloride
Propranolol Hydrochloride
propranololo
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor line
Reducor Line
Rexigen
Sagittol
Sawatal
Servanolol
Sloprolol
SPBio_001361
SPBio_001658
SPBio_003093
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
STK735510
Sumial
Tesnol
UNII-9Y8NXQ24VQ
β-Propranolol
Î’-propranolol
|
|
12 |
|
Midodrine |
Approved |
Phase 4 |
|
42794-76-3, 133163-28-7 |
4195 |
Synonyms:
( -)-Midodrin hydrochloride
( -)-Midodrine hydrochloride
()-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol
(+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride
(+-)-2-Amino-N-(b-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-Midodrine hydrochloride
(+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol
(±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
(RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid
[+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride
2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride
2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide
2-Amino-N-(2,5-dimethoxy-b-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-β-hydroxyphenethyl)acetamide
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
3092-17-9
3092-17-9 (mono-hydrochloride)
42794-76-3
42794-76-3 (Parent)
43218-56-0
97476-58-9
A 4020 Linz
A-4020 Linz
AB00053715
AC1L1HMJ
AC1L2BU9
Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride
Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride
Alphamine
Amatine
BPBio1_000157
BRD-A79981887-003-05-7
BSPBio_000141
BSPBio_003150
C07890
C12H18N2O4
C12H18N2O4.HCl
Cahill may roberts brand OF midodrine monohydrochloride
CHEBI:31847
CHEBI:6933
CHEMBL1200461
Christiaens brand OF midodrine monohydrochloride
CID18340
CID4195
CPD000058833
D01307
D08220
DB00211
DivK1c_000955
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(b-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(Î’-hydroxy-2,5-dimethoxyphenethyl)glycinamid
EINECS 255-945-3
EINECS 256-148-3
Gutron
Hipertan
HMS1568H03
HMS1922O03
I06-0865
IDI1_000955
KBio1_000955
KBio2_002121
|
KBio2_004689
KBio2_007257
KBio3_002650
KBioGR_000763
KBioSS_002121
LS-174957
LS-8042
LS-8052
M8277_FLUKA
M8277_SIGMA
Metligene
Midamine
Midodrin
Midodrina
Midodrina [INN-Spanish]
midodrine
Midodrine
Midodrine (INN)
Midodrine [BAN:INN]
Midodrine [INN:BAN]
Midodrine HCL
Midodrine hydrochloride
MIDODRINE HYDROCHLORIDE
Midodrine hydrochloride (JAN/USAN)
Midodrine hydrochloride [USAN:JAN]
Midodrine hydrochloride [USAN]
Midodrine monohydrochloride
Midodrine Monohydrochloride
Midodrinum
Midodrinum [INN-Latin]
Midon
MLS001332567
MLS001332568
MLS002154233
MolPort-003-666-473
MolPort-003-849-221
Monohydrochloride, midodrine
N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide
N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide
NCGC00095311-01
NCGC00178238-01
NCGC00178238-02
NINDS_000955
Nycomed brand OF midodrine monohydrochloride
Prestwick_625
Prestwick0_000191
Prestwick1_000191
Prestwick2_000191
Prestwick3_000191
ProAmatine
Pro-Amatine
Pro-Amatine (TN)
SAM002564219
SBB066174
Shire brand OF midodrine monohydrochloride
SMR000058833
SPBio_001390
SPBio_002062
Spectrum_001641
SPECTRUM1503257
Spectrum2_001545
Spectrum3_001585
Spectrum4_000192
Spectrum5_000962
St 1085
St. Peter 224
ST-1085
TL8002369
TS 701
UNII-59JV96YTXV
UNII-6YE7PBM15H
|
|
13 |
|
Ornithine |
Approved, Nutraceutical |
Phase 4 |
|
70-26-8, 3184-13-2 |
6262 |
Synonyms:
(+)-S-Ornithine
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-2,5-Diaminovalerate
(S)-2,5-diaminovaleric acid
(S)-2,5-Diaminovaleric acid
(S)-a,D-Diaminovalerate
(S)-a,D-Diaminovaleric acid
(S)-a,delta-Diaminovalerate
(S)-a,delta-Diaminovaleric acid
(S)-a,Δ-diaminovalerate
(S)-a,Δ-diaminovaleric acid
(S)-alpha,delta-Diaminovalerate
(S)-alpha,delta-Diaminovaleric acid
(S)-ornithine
(S)-Ornithine
(S)-Α,δ-diaminovalerate
(S)-α,δ-diaminovaleric acid
(S)-Α,δ-diaminovaleric acid
2,5 Diaminopentanoic acid
2,5-Diaminopentanoic acid
|
5-Amino-L-norvaline
L-(-)-Ornithine
levo-ornithine
L-Ornithine
Ornithine
Ornithine dihydrochloride, (L)-isomer
Ornithine hydrochloride, (D)-isomer
Ornithine hydrochloride, (DL)-isomer
Ornithine hydrochloride, (L)-isomer
Ornithine monoacetate, (L)-isomer
Ornithine monohydrobromide, (L)-isomer
Ornithine monohydrochloride, (D)-isomer
Ornithine monohydrochloride, (DL)-isomer
Ornithine phosphate (1:1), (L)-isomer
Ornithine sulfate (1:1), (L)-isomer
Ornithine, (D)-isomer
Ornithine, (DL)-isomer
Ornithine, (L)-isomer
Ornithinum
Ornitina
|
|
14 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 4 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-aminobutanedioic acid
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-aminosuccinic acid
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
Aspartic acid
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
15 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
68-26-8, 11103-57-4 |
445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
[11,12-3H]-Retinol
11103-57-4
11-cis-Retinol
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
alin
all trans Retinol
All Trans Retinol
All-trans retinol
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-retinol
all-trans-Retinol
all-trans-retinyl alcohol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-vitamin A alcohol
all-trans-Vitamin a alcohol
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
Alphalin
Alphasterol
A-Mulsal
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol a
Aquasol A Parenteral
Aquasynth
AR-1L3057
A-Sol
Atars
ATAV
Avibon
A-Vi-Pel
Avita
A-Vitan
Avitol
Axerol
Axerophthol
Axerophtholum
Bentavit A
beta-Retinol
BIDD:PXR0102
Biosterol
b-Retinol
BRN 0403040
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
Chocola a
Chocola A
CID445354
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
Hi-A-Vita
|
HMS1921B04
HMS2092L13
HMS501I08
Homagenets Aoral
Homagenets aorl
HSDB 815
Hydrovit A
IDI1_000486
Lard Factor
LMPR01090001
LPK
LS-1578
M.V.C. 9+3
M.V.I.-12
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
Nio-A-Let
NSC 122759
NSC122759
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
retinol
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol-(cellular-retinol-binding-protein)
Retinol, all-trans- (8CI)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
Sehkraft A
SMP2_000102
SMR000112036
Solu-A
SPECTRUM1501203
Spectrum5_000993
Spectrum5_001997
ST057232
Super A
Testavol
Testavol S
Thalasphere
trans-retinol
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
tROL
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-a
Vi-Alpha
Vi-Dom-A
Vio-A
Vitamin a
Vitamin A
Vitamin- A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin- A alcohol
Vitamin A alcohol (VAN)
Vitamin- A alcohol solution
Vitamin A cryst
Vitamin a1
Vitamin A1
Vitamin- A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
Wachstumsvitamin
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
ZINC03831417
Zinosan N
|
|
16 |
|
Valine |
Approved, Nutraceutical |
Phase 4 |
|
72-18-4 |
6287 |
Synonyms:
(2S)-2-Amino-3-methylbutanoate
(2S)-2-Amino-3-methylbutanoic acid
(S)-2-Amino-3-methylbutanoate
(S)-2-Amino-3-methyl-butanoate
(S)-2-Amino-3-methylbutanoic acid
(S)-2-Amino-3-methyl-butanoic acid
(S)-2-Amino-3-methylbutyrate
(S)-2-Amino-3-methylbutyric acid
(S)-a-Amino-b-methylbutyrate
(S)-a-Amino-b-methylbutyric acid
(S)-alpha-Amino-beta-methylbutyrate
(S)-alpha-Amino-beta-methylbutyric acid
(S)-Valine
2-Amino-3-methylbutanoate
2-Amino-3-methylbutanoic acid
2-Amino-3-methylbutyrate
2-Amino-3-methylbutyric acid
L Valine
L-(+)-a-Aminoisovalerate
|
L-(+)-a-Aminoisovaleric acid
L-(+)-alpha-Aminoisovalerate
L-(+)-alpha-Aminoisovaleric acid
L-(+)-Α-aminoisovalerate
L-(+)-Α-aminoisovaleric acid
L-a-Amino-b-methylbutyrate
L-a-Amino-b-methylbutyric acid
L-alpha-Amino-beta-methylbutyrate
L-alpha-Amino-beta-methylbutyric acid
L-valin
L-Valin
L-valine
L-Α-amino-β-methylbutyrate
L-Α-amino-β-methylbutyric acid
V
Val
Valine
VALINE
|
|
17 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
18 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
19 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
20 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
21 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
22 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
23 |
|
Protective Agents |
|
Phase 4 |
|
|
|
24 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
25 |
|
N-Methylaspartate |
|
Phase 4 |
|
|
|
26 |
|
Antioxidants |
|
Phase 4 |
|
|
|
27 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
28 |
|
retinol |
|
Phase 4 |
|
|
|
29 |
|
Retinol palmitate |
|
Phase 4 |
|
|
|
30 |
|
Anesthetics |
|
Phase 4 |
|
|
|
31 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
32 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
33 |
|
Narcotics |
|
Phase 4 |
|
|
|
34 |
|
Histamine Antagonists |
|
Phase 4 |
|
|
|
35 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
36 |
|
Histamine Phosphate |
|
Phase 4 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
37 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
38 |
|
Analgesics |
|
Phase 4 |
|
|
|
39 |
|
Histamine H1 Antagonists |
|
Phase 4 |
|
|
|
40 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
41 |
|
Narcotic Antagonists |
|
Phase 4 |
|
|
|
42 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
43 |
|
Antiemetics |
|
Phase 4 |
|
|
|
44 |
|
Buprenorphine, Naloxone Drug Combination |
|
Phase 4 |
|
|
|
45 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
46 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
47 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
48 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
49 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
50 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 158)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy |
Unknown status |
NCT01178372 |
Phase 4 |
Lactulose;Probiotics(VSL#3) |
2 |
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study |
Unknown status |
NCT03077217 |
Phase 4 |
Rifaximin |
3 |
Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics |
Unknown status |
NCT01356121 |
Phase 4 |
Propofol;Midazolam |
4 |
Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose |
Unknown status |
NCT01175538 |
Phase 4 |
Lactulose;Lactulose |
5 |
Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy |
Unknown status |
NCT02401490 |
Phase 4 |
Human albumin;Placebo |
6 |
Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy |
Unknown status |
NCT03100513 |
Phase 4 |
Lactulose;Polyethylene Glycol |
7 |
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study |
Unknown status |
NCT00896831 |
Phase 4 |
L-ornithine-L-aspartate;placebo |
8 |
Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis |
Unknown status |
NCT02470546 |
Phase 4 |
Metformin;Placebo |
9 |
LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial |
Completed |
NCT01847651 |
Phase 4 |
LOLA or placebo |
10 |
Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt |
Completed |
NCT01559519 |
Phase 4 |
Albumin |
11 |
The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. |
Completed |
NCT01041755 |
Phase 4 |
L-ornithine-L-aspartate;Lactose |
12 |
Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy |
Completed |
NCT00740142 |
Phase 4 |
L-ornithine-L-aspartate and lactulose;placebo and lactulose |
13 |
Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients |
Completed |
NCT02158182 |
Phase 4 |
Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo |
14 |
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life |
Completed |
NCT00375375 |
Phase 4 |
Lactulose |
15 |
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy |
Completed |
NCT01842581 |
Phase 4 |
Rifaximin;Lactulose |
16 |
Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis |
Completed |
NCT04736836 |
Phase 4 |
Rifaximin |
17 |
Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. |
Completed |
NCT00886925 |
Phase 4 |
Albumin;Sodium chloride 0.9% |
18 |
Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study |
Completed |
NCT00955500 |
Phase 4 |
|
19 |
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers |
Completed |
NCT01846455 |
Phase 4 |
2.0mg Buprenorphine/0.5mg Naloxone;Promethazine |
20 |
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension |
Completed |
NCT01059396 |
Phase 4 |
propranolol;carvedilol;placebo |
21 |
Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial |
Completed |
NCT01722578 |
Phase 4 |
L-ornithine L-aspartate;Placebo |
22 |
A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy |
Completed |
NCT02019784 |
Phase 4 |
Rifaximin-α;Placebo Oral Tablet |
23 |
Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation |
Completed |
NCT00839358 |
Phase 4 |
albumin;Midodrine;Placebo |
24 |
Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study |
Recruiting |
NCT03987893 |
Phase 4 |
PEG-3350 with Electolytes;Lactulose |
25 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy |
Recruiting |
NCT01846663 |
Phase 4 |
Placebo;Rifaximin |
26 |
Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. |
Recruiting |
NCT04073290 |
Phase 4 |
Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution |
27 |
Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) |
Recruiting |
NCT04436601 |
Phase 4 |
Polyethylene Glycols;Lactulose |
28 |
Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology |
Terminated |
NCT01824589 |
Phase 4 |
|
29 |
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. |
Terminated |
NCT01842113 |
Phase 4 |
Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo |
30 |
Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease |
Withdrawn |
NCT01654939 |
Phase 4 |
Rifaximin |
31 |
A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy |
Unknown status |
NCT02464124 |
Phase 2, Phase 3 |
Nitazoxanide;Lactulose |
32 |
Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. |
Unknown status |
NCT01798329 |
Phase 3 |
|
33 |
Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage |
Unknown status |
NCT00553423 |
Phase 3 |
Lactulose;Placebo |
34 |
13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure |
Completed |
NCT02786836 |
Phase 2, Phase 3 |
13C-Methacetin |
35 |
A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. |
Completed |
NCT00248625 |
Phase 3 |
N-acetylcysteine;Placebo |
36 |
Efficacy of a Three Days' Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study |
Completed |
NCT00433368 |
Phase 3 |
L-Ornithine L-Aspartate |
37 |
Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation |
Completed |
NCT01110447 |
Phase 2, Phase 3 |
VSL#3 |
38 |
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy |
Completed |
NCT00298038 |
Phase 3 |
Rifaximin;Placebo |
39 |
A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy |
Completed |
NCT00686920 |
Phase 3 |
Rifaximin |
40 |
Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial |
Completed |
NCT01556646 |
Phase 3 |
Tolvaptan |
41 |
Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life |
Completed |
NCT01008293 |
Phase 2, Phase 3 |
VSL#3;Lactulose |
42 |
Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy |
Completed |
NCT02173132 |
Phase 3 |
Acetyl-L-carnitine |
43 |
Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy |
Recruiting |
NCT04161053 |
Phase 3 |
Rifaximin;Nitazoxanide |
44 |
Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients |
Not yet recruiting |
NCT04244877 |
Phase 3 |
Rifaximin |
45 |
A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure |
Terminated |
NCT01829347 |
Phase 3 |
|
46 |
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial |
Terminated |
NCT00364689 |
Phase 3 |
Rifaximin;Lactulose |
47 |
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure |
Withdrawn |
NCT02086825 |
Phase 3 |
Rifaximin;Lactulose |
48 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of MNK6105 (an Intravenous Formulation of L-Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Hyperammonemia Associated With an Episode of Hepatic Encephalopathy |
Withdrawn |
NCT04128462 |
Phase 3 |
MNK-6105;Placebo;Standard of Care |
49 |
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy |
Unknown status |
NCT00281502 |
Phase 2 |
Rifaximin (drug) |
50 |
Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study |
Unknown status |
NCT01690845 |
Phase 2 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
51
:
Kanamycin Sulfate
Lactulose
|
NEOMYCIN SO4 PWDR
|
|